Zimmer Biomet Continues Turnaround Lead by ROSA Robot

 
• By Reed Miller

Zimmer Biomet’s net sales were up 1.2% year-over-year in the second quarter. CEO Bryan Hanson said the ROSA Knee robotic surgery system is performing even better than expected since it launched earlier this year, and is expected to be an important revenue-driver in the future.

Milan, Italy - November 1, 2017: Zimmer Biomet Holdings logo on the website homepage. - Image
• Source: shutterstock.com

Zimmer Biomet Holdings Inc. says its long-term plan to return to steady growth is ahead of schedule.

The orthopedics company is still overcoming the quality and supply challenges that emerged when Zimmer and Biomet merged in 2015. (Also see "Earnings Winners and Losers: JNJ, MMSI, ABT, ZBH, SNN, EW, Plus Round-Up" - Medtech Insight, 8 May, 2017.) Since Bryan Hanson became CEO in late 2017, the company has been restructuring its businesses to streamline reporting and decision-making, changing at least 70% of the leadership team

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Orthopedics

More from Device Area